Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

peginterferon alfa-2a × Tumor-Agnostic × Clear all

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Myeloid 10 Other hematologic neoplasm 7 Gastrointestinal 7 Dermatologic 5 Lymphoid 2 CNS 2 Tumor-Agnostic 1 Sarcoma 1 Other solid neoplasm 1 Genitourinary 1 Breast 1

Conditions

Carcinoma, Squamous Cell 1

Interventions

pembrolizumab 87 Paclitaxel 79 Gemcitabine 73 Carboplatin 72 Surveys and Questionnaires 60 Nivolumab 53 Cisplatin 53 Bevacizumab 53 Docetaxel 52 Magnetic Resonance Spectroscopy 46 Blood Specimen Collection 45 Fluorouracil 44 Capecitabine 44 Radiotherapy 41 Irinotecan 36 Oxaliplatin 34 Erlotinib Hydrochloride 34 Biopsy 34 Specimen Handling 31 Leucovorin 31 Standard of Care 30 Pemetrexed 30 atezolizumab 28 Trastuzumab 28 Radiosurgery 27 Cetuximab 26 Sorafenib 25 Everolimus 25 Cyclophosphamide 25 Ipilimumab 24

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT05729139 2023-08-09

Cemiplimab/Peg-Interferon-α in Advanced CSCC

Baptist Health South Florida

Phase 1 Withdrawn

Carcinoma, Squamous Cell

Data powered by HemOnc (CC BY 4.0) Colophon ⚡